Prothena spikes on Phase I Parkinson's data
This article was originally published in Scrip
Shares in Elan spin-out Prothena shot up by as much as 37% to $40.14 on Nasdaq on 20 March on the back of Phase I data for its experimental Parkinson's disease therapy PRX002. The monoclonal antibody product is being developed under a worldwide collaboration with Roche for antibodies targeting alpha-synuclein that was signed in late 2013. PRX002 was safe and well-tolerated, meeting the primary objective of the study, and further results showed that administration of PRX002 led to rapid and dose-dependent reductions of free serum alpha-synuclein levels of up to 96% (p<0.00001).>0.00001).>
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.